The Genitourinary Cancer Channel

Explore the latest updates, including expert interviews and features

The GU Cancer Channel on VJOncology is supported by an educational grant from Pfizer Inc. and Merck KGaA. These supporters have no influence over the production of the content.

Latest videos VJSessions Subtypes Topics Conferences Features Editorial Board

Welcome to the Genitourinary (GU) Cancer Channel!

Explore the latest updates presented at major international congresses in the form of video interviews, podcasts and roundtable discussions featuring members of our expert Editorial Board.

Exciting advances are being made in the field of genitourinary cancer, including checkpoint inhibitor treatments, new non-steroidal anti-androgens, chemoimmunotherapy combinations and predictive biomarkers.

GU Cancer Videos by Subtype

Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer
Penile Cancer
1:55
Latest advances in tumour genetics research for prostate cancer
Omar Mian • 25 Oct 2022
2:58
Genomic classifiers for prostate cancer risk statification
Omar Mian • 25 Oct 2022
0:48
Future research on SRT plus enzalutamide for PSA recurrent high-risk prostate cancer
Phuoc Tran • 25 Oct 2022
2:53
Use of salvage radiation therapy for biochemical recurrence of prostate cancer after prostatectomy
Alan Dal Pra • 27 Oct 2022
View All Videos
2:05
Improving responses to trimodality therapy in patients with muscle-invasive bladder cancer
Sophia Kamran • 3 Nov 2022
2:35
Genomic determinants of response to TMT for patients with muscle-invasive bladder cancer
Sophia Kamran • 3 Nov 2022
4:00
2022 WHO classification: updates in bladder cancer
Eva Compérat • 19 Oct 2022
4:04
Genomic and tumor characterisation of upper tract urothelial carcinoma
Eva Compérat • 19 Oct 2022
View All Videos
1:05
Cohort 1 LITESPARK-003: belzutifan + cabozantinib 1L treatment for advanced RCC
Toni Choueiri • 12 Sep 2022
3:31
Perioperative strategies in high-risk and oligometastatic renal cell and urothelial cancers
Enrique Grande • 10 Sep 2022
0:59
Updates in kidney cancer at ESMO 2022
Joaquim Bellmunt • 12 Sep 2022
4:12
Kidney cancer at ESMO 2022: KEYNOTE-564 and PROSPER
Ramaprasad Srinivasan • 20 Sep 2022
View All Videos
7:05
TRISST: MRI versus FDG-PET-CT for the treatment of testicular cancer
Tahlita Zuiverloon • 15 Jul 2021
3:40
Surgery in metastatic germ cell tumors to reduce disease burden and improve long-term outcomes
Peter Albers • 8 Jul 2021
3:34
Benefits of circulating miRNAs for follow-up of patients with seminoma
Matthew Murray • 1 Jul 2021
1:12
miR-371a-3p microRNA panel alone is sufficient for diagnosis and monitoring
Matthew Murray • 1 Jul 2021
View All Videos
3:18
RCC & penile cancer at ASCO GU: KN-564, NeoAvAx & PERICLES
Jen-Jane Liu • 18 Feb 2022
5:44
Long-term outcomes of DSNB for cN0 penile cancer
Edoardo Pozzi • 10 Jul 2021
2:06
c-MET receptor-targeted fluorescence for image-guided surgery in PSCC
Hielke-Martijn De Vries • 7 Jul 2021
3:14
Factors impacting additional tumour-bearing lymph nodes at completion ILND after positive DSNB
Hielke-Martijn De Vries • 7 Jul 2021
View All Videos

Topics

Trial Updates
Molecular Profiling
Immuno-Oncology
Diagnosis
Imaging
2:35
Genomic determinants of response to TMT for patients with muscle-invasive bladder cancer
Sophia Kamran • 3 Nov 2022
2:58
Genomic classifiers for prostate cancer risk statification
Omar Mian • 25 Oct 2022
2:53
Use of salvage radiation therapy for biochemical recurrence of prostate cancer after prostatectomy
Alan Dal Pra • 27 Oct 2022
3:46
Results of the Phase III SAKK 09/10 trial of biomarkers for prostate cancer
Alan Dal Pra • 27 Oct 2022
View All Videos
2:56
Computational genomic approaches to treatment of genitourinary cancers
Sophia Kamran • 3 Nov 2022
2:35
Genomic determinants of response to TMT for patients with muscle-invasive bladder cancer
Sophia Kamran • 3 Nov 2022
1:55
Latest advances in tumour genetics research for prostate cancer
Omar Mian • 25 Oct 2022
2:58
Genomic classifiers for prostate cancer risk statification
Omar Mian • 25 Oct 2022
View All Videos
2:05
Improving responses to trimodality therapy in patients with muscle-invasive bladder cancer
Sophia Kamran • 3 Nov 2022
5:15
Combination myeloid cell and T-cell targeting as an effective anti-tumor strategy
Judith Varner • 3 Nov 2022
0:28
Immunotherapy + chemotherapy for bladder cancer
Chong Xian Pan • 27 Sep 2022
1:50
Potentiating immunotherapy for bladder cancer via porphyrin-based PLZ4-nanoparticles
Chong Xian Pan • 27 Sep 2022
View All Videos
5:53
Real-world associations between PSA screening and metastatic prostate cancer incidence
Alex Bryant • 17 Oct 2022
3:09
Is PSA is the best biomarker to use for prostate cancer detection?
Alex Bryant • 17 Oct 2022
3:19
Is there benefit for screening all men, not just those who are high-risk, for prostate cancer?
Alex Bryant • 17 Oct 2022
3:20
Clinical applications of PSMA
Neil Bander • 12 Sep 2022
View All Videos
2:53
Use of salvage radiation therapy for biochemical recurrence of prostate cancer after prostatectomy
Alan Dal Pra • 27 Oct 2022
4:33
APCCC 2022: PSMA-PET, adjuvant radiotherapy vs early salvage radiotherapy
Silke Gillessen • 18 Oct 2022
3:12
BladderPath: reducing bladder treatment times with MRI scans
Nicholas James • 9 Sep 2022
1:24
Improving the diagnosis of bladder cancer in the BladderPath study
Nicholas James • 9 Sep 2022
View All Videos

Conferences

ESMO 2022
EAU 2022
ASCO 2022
AACR 2022
GU Cancers 2022
ESMO 2021
0:22
The unmet needs of patients with prostate cancer
Daniel Petrylak • 10 Sep 2022
1:37
ARCHES: OS in mHSPC who recieved prior ADT and reached low PSA further treated with enzalutamide
Daniel Petrylak • 11 Sep 2022
1:05
Cohort 1 LITESPARK-003: belzutifan + cabozantinib 1L treatment for advanced RCC
Toni Choueiri • 12 Sep 2022
1:17
DS-7300 demonstrates durable antitumor activity in advanced solid tumors
Toshihiko Doi • 10 Sep 2022
View All Videos
2:15
Analyzing the role of oncolytic viruses in prostate cancer
Geertje Van Der Horst • 28 Jun 2022
2:40
Limitations of oncolytic viral therapy
Geertje Van Der Horst • 28 Jun 2022
4:22
Ongoing studies assessing oncolytic virotherapy in urological malignancies
Geertje Van Der Horst • 28 Jun 2022
2:30
The importance of TURBT in bladder cancer management
Kevin Gallagher • 29 Jun 2022
View All Videos
1:13
Promising future of PSMA for prostate cancer
Eugene Shenderov • 10 Jun 2022
6:57
Phase II trial of enoblituzumab for patients with intermediate/high-risk localised prostate cancer
Eugene Shenderov • 10 Jun 2022
1:59
Next steps for belzutifan for Von Hippel-Lindau syndrome
Ramaprasad Srinivasan • 17 Jun 2022
13:17
Belzutifan for Von Hippel-Lindau syndrome
Ramaprasad Srinivasan • 17 Jun 2022
View All Videos
0:18
Future research directions for the novel PD-1 and CTLA-4 bispecific checkpoint inhibitor, MEDI5752
Ben Tran • 21 Apr 2022
4:28
Update on PETRA trial investigating a next-generation PARP1 select inhibitor
Timothy Yap • 13 Apr 2022
3:30
Radionuclide conjugates 225Ac-J591 and 177Lu-PSMA-I&T for mCRPC
Scott Tagawa • 11 Apr 2022
1:14
Anti-CAIX immune restoring CAR T-cells reverse immunosuppressive TME
Yufei Wang • 11 Apr 2022
View All Videos
3:42
ctDNA level variation as an early predictor of survival in patients with mCRPC
Vincenza Conteduca • 15 Feb 2022
0:53
Unanswered questions in the management of clear cell RCC
Mehmet Bilen • 19 Feb 2022
1:18
URO-12: Importance of collaboration between institutions in clinical trials
Massimo Di Maio • 3 Mar 2022
2:20
Future of PARP inhibitors for urothelial carcinoma
Massimo Di Maio • 3 Mar 2022
View All Videos
5:28
Importance of real-world data in clinical trials
Janet E. Brown • 19 Sep 2021
2:21
PRISM: importance of investigating the scheduling of treatment regimens for RCC
Janet E. Brown • 19 Sep 2021
2:34
First-line treatments for patients with mHSPC and mCRPC
Richard Cathomas • 27 Sep 2021
2:06
SAKK 08/16: darolutamide maintenance therapy for previously treated patients with mCRPC
Richard Cathomas • 27 Sep 2021
View All Videos

The GU Cancer Channel on VJOncology is supported by an educational grant from Pfizer Inc. and Merck KGaA.

These supporters have no influence over the production of the content.

VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals